Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Lexaria Bioscience (LEXX) over the last 14 years, with Q4 2025 value amounting to $1.5 million.

  • Lexaria Bioscience's Total Current Liabilities rose 38910.13% to $1.5 million in Q4 2025 from the same period last year, while for Nov 2025 it was $1.5 million, marking a year-over-year increase of 38910.13%. This contributed to the annual value of $1.5 million for FY2025, which is 3584.11% up from last year.
  • Per Lexaria Bioscience's latest filing, its Total Current Liabilities stood at $1.5 million for Q4 2025, which was up 38910.13% from $1.5 million recorded in Q3 2025.
  • Lexaria Bioscience's 5-year Total Current Liabilities high stood at $1.8 million for Q1 2025, and its period low was $81717.0 during Q1 2024.
  • Moreover, its 5-year median value for Total Current Liabilities was $252717.0 (2021), whereas its average is $571316.2.
  • Per our database at Business Quant, Lexaria Bioscience's Total Current Liabilities tumbled by 8522.14% in 2024 and then soared by 213015.53% in 2025.
  • Over the past 5 years, Lexaria Bioscience's Total Current Liabilities (Quarter) stood at $237699.0 in 2021, then increased by 18.44% to $281520.0 in 2022, then tumbled by 55.77% to $124523.0 in 2023, then surged by 139.15% to $297798.0 in 2024, then surged by 389.1% to $1.5 million in 2025.
  • Its Total Current Liabilities was $1.5 million in Q4 2025, compared to $1.5 million in Q3 2025 and $1.5 million in Q2 2025.